{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T21:58:14Z","timestamp":1777759094286,"version":"3.51.4"},"reference-count":27,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>People affected by diabetes mellitus (DM), chronic kidney disease (CKD), or heart failure are often prescribed sodium\u2013glucose cotransporter-2 inhibitors (SGLT2is) as a method of treatment. These drugs favorably affect glucose metabolism, as patients taking them have lower serum glucose levels. Another promising positive impact is protection against microvascular damage, cardiovascular disease, and chronic kidney disease. Nevertheless, fungal infections, urinary tract infections, and ketoacidosis are the adverse effects that might happen during the SGLT2i treatment. Fungal infections are more common among patients treated with these medications, including vulvovaginal Candidiasis in women and balanitis or balanoposthitis in men. Given the difficulty of treating fungal infections in patients with co-occurring diseases, we recommend that ongoing supervision of patients treated with SGLT2i include prevention and early detection of fungal infections.<\/jats:p>","DOI":"10.3390\/jcm15093395","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T12:31:56Z","timestamp":1777465916000},"page":"3395","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["SGLT2 Inhibitors in Clinical Practice: Cardiorenal Benefits and Risk of Fungal Infections\u2014A Nephrologist\u2019s Perspective"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-1827-6387","authenticated-orcid":false,"given":"Wiktoria","family":"Andryszkiewicz","sequence":"first","affiliation":[{"name":"Faculty of Medicine, Wroclaw Medical University, 50-367 Wroclaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zuzanna","family":"Cichowska","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Wroclaw Medical University, 50-367 Wroclaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7490-0832","authenticated-orcid":false,"given":"Maria","family":"Kr\u0119cicka","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Wroclaw Medical University, 50-367 Wroclaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0764-4939","authenticated-orcid":false,"given":"S\u0142awomir","family":"Zmonarski","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Transplantation Medicine and Internal Diseases, Wroclaw Medical University, 50-367 Wroclaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1093\/ckj\/sfad082","article-title":"EMPA-KIDNEY: Expanding the Range of Kidney Protection by SGLT2 Inhibitors","volume":"16","author":"Sarafidis","year":"2023","journal-title":"Clin. Kidney J."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Chewcharat, A., Prasitlumkum, N., Thongprayoon, C., Bathini, T., Medaura, J., Vallabhajosyula, S., and Cheungpasitporn, W. (2020). Efficacy and Safety of SGLT-2 Inhibitors for Treatment of Diabetes Mellitus among Kidney Transplant Patients: A Systematic Review and Meta-Analysis. Med. Sci., 8.","DOI":"10.3390\/medsci8040047"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Di Costanzo, A., Esposito, G., Indolfi, C., and Spaccarotella, C.A.M. (2023). SGLT2 Inhibitors: A New Therapeutical Strategy to Improve Clinical Outcomes in Patients with Chronic Kidney Diseases. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24108732"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Jabbour, S.A., Ibrahim, N.E., and Argyropoulos, C.P. (2022). Physicians\u2019 Considerations and Practice Recommendations Regarding the Use of Sodium-Glucose Cotransporter-2 Inhibitors. J. Clin. Med., 11.","DOI":"10.3390\/jcm11206051"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"E1128","DOI":"10.1503\/cmaj.190047","article-title":"Sodium-Glucose Cotransporter Inhibitors in Type 2 Diabetes: Thinking beyond Glucose Lowering","volume":"191","author":"Neuen","year":"2019","journal-title":"CMAJ"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1007\/s003450050167","article-title":"Fungal Infections of the Urinary Tract","volume":"17","author":"Sobel","year":"1999","journal-title":"World J. Urol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1177\/1060028020951928","article-title":"Prevention and Management of Genital Mycotic Infections in the Setting of Sodium-Glucose Cotransporter 2 Inhibitors","volume":"55","author":"Engelhardt","year":"2021","journal-title":"Ann. Pharmacother."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1111\/dom.13820","article-title":"Sodium Glucose Cotransporter 2 Inhibitors and Risk of Genital Mycotic and Urinary Tract Infection: A Population-Based Study of Older Women and Men with Diabetes","volume":"21","author":"Lega","year":"2019","journal-title":"Diabetes Obes. Metab."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"282","DOI":"10.14744\/cpr.2024.60933","article-title":"Urinary Tract Infections and Fungal Infections Associated with SGLT-2 Inhibitors and Metformin Combination: A Real-World Study from 2013 to 2023 Based on FAERS Database","volume":"46","author":"Aksoyalp","year":"2024","journal-title":"J. Clin. Pract. Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"102736","DOI":"10.1016\/j.autneu.2020.102736","article-title":"Autonomic Neuropathy and Urologic Complications in Diabetes","volume":"229","author":"Wessells","year":"2020","journal-title":"Auton. Neurosci."},{"key":"ref_11","first-page":"129","article-title":"Urinary Tract Infections in Patients with Type 2 Diabetes Mellitus: Review of Prevalence, Diagnosis, and Management","volume":"8","author":"Nitzan","year":"2015","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.pcd.2017.06.004","article-title":"Clinical Risk Factors Predicting Genital Fungal Infections with Sodium\u2013Glucose Cotransporter 2 Inhibitor Treatment: The ABCD Nationwide Dapagliflozin Audit","volume":"12","author":"Thong","year":"2018","journal-title":"Prim. Care Diabetes"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Abdelrahman, A.M., Awad, A.S., and Abdel-Rahman, E.M. (2024). Sodium-Glucose Co-Transporter 2 Inhibitors: Mechanism of Action and Efficacy in Non-Diabetic Kidney Disease from Bench to Bed-Side. J. Clin. Med., 13.","DOI":"10.20944\/preprints202401.0901.v1"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1016\/j.jacc.2024.01.040","article-title":"Genitourinary Tract Infections in Patients Taking SGLT2 Inhibitors","volume":"83","author":"Kittipibul","year":"2024","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Gorgojo-Mart\u00ednez, J.J., G\u00f3rriz, J.L., Cebri\u00e1n-Cuenca, A., Castro Conde, A., and Velasco Arribas, M. (2024). Clinical Recommendations for Managing Genitourinary Adverse Effects in Patients Treated with SGLT-2 Inhibitors: A Multidisciplinary Expert Consensus. J. Clin. Med., 13.","DOI":"10.3390\/jcm13216509"},{"key":"ref_16","unstructured":"Imam, T.H. (2025, March 06). Fungal Urinary Tract Infections-Genitourinary Disorders-MSD Manual Professional Edition. Available online: https:\/\/www.msdmanuals.com\/professional\/genitourinary-disorders\/urinary-tract-infections-utis\/fungal-urinary-tract-infections."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Li, C.X., Liu, L.Y., Zhang, C.X., Geng, X.H., Gu, S.M., Wang, Y.Q., Liu, H., Xie, Q., and Liang, S. (2023). Comparative Safety of Different Sodium-Glucose Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. Front. Endocrinol., 14.","DOI":"10.3389\/fendo.2023.1238399"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Confederat, L.-G., Dragostin, O.-M., and Condurache, M.-I. (2025). SGLT2 Inhibitors and the Risk of Urogenital Infections: A Concise Review. J. Clin. Med., 14.","DOI":"10.3390\/jcm14061960"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1007\/s00345-019-02991-5","article-title":"Candida Urinary Tract Infections in Adults","volume":"38","author":"Odabasi","year":"2020","journal-title":"World J. Urol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1007\/s13300-018-0481-6","article-title":"Adverse Drug Events Associated with Sitagliptin Versus Canagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus: A Systematic Comparison Through a Meta-Analysis","volume":"9","author":"Bundhun","year":"2018","journal-title":"Diabetes Ther."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Benedict, K., Lyman, M., and Jackson, B.R. (2022). Possible Misdiagnosis, Inappropriate Empiric Treatment, and Opportunities for Increased Diagnostic Testing for Patients with Vulvovaginal Candidiasis\u2014United States, 2018. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0267866"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3810\/pgm.2013.05.2650","article-title":"Genital Mycotic Infections in Patients With Diabetes","volume":"125","author":"Nyirjesy","year":"2013","journal-title":"Postgrad. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.2337\/dci22-0027","article-title":"Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"45","author":"Khunti","year":"2022","journal-title":"Diabetes Care"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S2213-8587(20)30162-5","article-title":"Effects of the SGLT2 Inhibitor Dapagliflozin on Proteinuria in Non-Diabetic Patients with Chronic Kidney Disease (DIAMOND): A Randomised, Double-Blind, Crossover Trial","volume":"8","author":"Cherney","year":"2020","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.idc.2015.10.004","article-title":"The Global Burden of Fungal Diseases","volume":"30","author":"Vallabhaneni","year":"2016","journal-title":"Infect. Dis. Clin. N. Am."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1086\/421946","article-title":"Nosocomial Bloodstream Infections in US Hospitals: Analysis of 24,179 Cases from a Prospective Nationwide Surveillance Study","volume":"39","author":"Wisplinghoff","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Roddick, A.J., Wonnacott, A., Webb, D., Watt, A., Watson, M.A., Staplin, N., Riding, A., Lioudaki, E., Kuverji, A., and El Kossi, M. (2023). UK Kidney Association Clinical Practice Guideline: Sodium-Glucose Co-Transporter-2 (SGLT-2) Inhibition in Adults with Kidney Disease 2023 UPDATE. BMC Nephrol., 24.","DOI":"10.1186\/s12882-023-03339-3"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/9\/3395\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T13:21:16Z","timestamp":1777468876000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/9\/3395"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":27,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["jcm15093395"],"URL":"https:\/\/doi.org\/10.3390\/jcm15093395","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,29]]}}}